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Background: High interobserver variation is a well known drawback of conventional tumor regression grading, and
reaching consensus among pathologists may require a considerable effort. Therefore, in this study, morphometry
was tried to assess tumor regression, and its prognostic role was explored.
Methods: Tumor regression was quantified by a point counting method to yield tumor area fraction (TAF) as an
index of remaining vital tumor.
Results: In a series of 104 patients with clinically advanced rectal cancer treated with neoadjuvant radiochemotherapy,
TAFs were distributed continuously towards complete regression which was observed in 8.7% of the cases. Plotting
TAFs grouped by a conventional regression grading (Dworak’s) revealed considerable overlap between groups. In a
control series of untreated cancers, only TAFs of cancers with an expansive invasive border were setoff clearly from
TAFs obtained for the study cases, but TAFs of control cases with an infiltrative invasive border and mucinous
carcinomas extended well into the range of TAFs recorded for regressing tumors. Locoregional recurrence (N = 10) was
significantly associated with perineural tumor infiltration and capsule transgressing lymph node metastasis/tumor
deposits but not with the degree of tumor regression. Overall survival was better for patients with major regressions
(≤20th percentile by morphometry, or Dworak regression grade (DRG) 4/5), although statistical significance was
not reached.
Conclusions: Morphometry of tumor regression is feasible and explains why conventional regression grading is
so difficult to perform. Assessment of tumor regression, by subjective grading or morphometry, does not appear
to convey major prognostic information, at least not substantially beyond histopathological tumor staging. This
observation discourages expending too much effort on developing this aspect of the pathomorphological workup of
the resection specimens.
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Although neoadjuvant treatment of rectal cancer is a
routine procedure, some clinicopathological aspects of
neoadjuvant treatment remain difficult, even so many
years after its introduction. Namely, the problem of
making robust judgments on tumor regression by surgi-
cal pathologists has not been solved satisfactorily. Trad-
itionally, histopathologists grade regression of cancer* Correspondence: friedrich.prall@med.uni-rostock.de
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sidual tumor and features of the adjacent stroma.
Current systems are variations on one of two main
themes: by one approach (for example, the Dworak sys-
tem [1]) wherein pathologists assess residual vital tumor
in relation to that part of the surrounding stroma or
extracellular matrix with characteristic features of
regressing tumor; by the other approach, pathologists
make a mental sketch of a hypothetical ‘tumor bed’ and
then estimate the percentage of vital remaining tumor in
this region [2]. Whichever approach is chosen, regres-
sion grading is a subjective procedure and interobserveris is an Open Access article distributed under the terms of the Creative
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institutional setting [3], although better performance has
been reported for a single-institution series [4]. Morpho-
metric assessment of tumor regression has not been re-
ported so far.
In most published studies, clinicopathological TNM
stage is superior to or at least as important as the grade
of tumor regression in predicting survival of rectal can-
cer patients. However, a dedicated histopathological
workup of resection specimens could supply information
of potential prognostic value beyond TNM. Specifically,
histopathological features that may be worth paying at-
tention to in this respect are: measuring depth of extra-
mural infiltration, recording transgression of the lymph
node capsule by metastatic tumor, as well as angioinva-
sion and perineural invasion. Status of the resection
margin with measurement of distances is well appreci-
ated as relevant [5].
In this study, we used our cases of clinically advanced,
neoadjuvantly treated rectal cancers accessioned in the
years 2000 to 2010 to test the prognostic potential of an
assessment of tumor regression that relies on metric
data and to compare these with conventional regression
grading. Furthermore, in a study review, the histopatho-
logical features mentioned above were recorded and
their impact on local recurrence was explored.
Methods
Composition of the study series and clinical data
This study includes all patients who underwent neoadju-
vant long-term intensified chemoradiation for a clinically
advanced, biopsy-proven adenocarcinoma of the rectum
(0 to 16 cm from the anal verge) in the years 2000 to
2010 in the Department of Radiotherapy, Rostock Univer-
sity and who subsequently were operated in the Depart-
ment of Surgery, Rostock University; histopathological
examination of the resection specimens was done in the
Institute of Pathology, Rostock University. Seventy-six pa-
tients were men, 28 were women, age 21 to 79 years
(mean 61.98 years, median 63.87 years). For pretherapeu-
tic clinical staging, a clinical history of the patients was
taken and patients had a clinical examination as well as
rigid rectoscopy to determine the distance of the lowest
tumor border from the anal verge, colonoscopy, endoso-
nographic ultrasound and/or imaging studies of the pelvis
(MRI or CT), a CT scan and/or ultrasound examination of
the abdomen, liver function tests, and chest X-ray, or CT
of the thorax; additional imaging studies were done in the
case of suspected metastatic disease. Details of the neoad-
juvant therapy and the surgical procedures have been pub-
lished previously [6]. Briefly, patients received pelvic
radiation of 1.8 Gy single dose five days a week, adding up
to 50.4 Gy (years 2000 to 2002; N = 20) or 55.8 Gy (after
2002; N = 84); this was complemented by chemotherapywith 5-FU or capecetabine and irinotecan or oxaliplatin.
Surgery was scheduled six weeks after neoadjuvant treat-
ment and included a total mesorectal excision for cancers
of the low (0 to < 6 cm) and middle (6 to <12 cm) rectum
and a partial mesorectal excision for cancers of the upper
rectum (12 to 16 cm).
Follow-up data were obtained by a systematic ap-
proach. A standardized questionnaire was circulated to
the referring physicians/primary care physicians at regu-
lar intervals requesting information on vital status, local
recurrence, and metachronous metastatic disease. In
addition, clinical information from the computerized
hospital database was integrated and a check on the pa-
tients’ vital status was made with the Berlin Central Can-
cer Registry where death certificates from all deaths
throughout Germany are recorded. Mean and median
follow-up times were 79.4 and 78.5 months, respectively.
The study was approved by the Medical Ethical Commit-
tee of Rostock University.
Pathomorphological examination of the resection
specimens
Surgical resection specimens were opened along the an-
terior aspect of the rectum and fixed overnight in buff-
ered formalin. Dissections were carried out according to
a standard in-house protocol that included blocking of
the complete tumor/residual lesion if below 3 cm in the
largest diameter and generous blocking in the remaining
cases (8.62 and 8.00 paraffin-blocks as mean and me-
dian, respectively). Distances between the tumor and the
circumferential margins were measured; paraffin-blocks
representing extramural residual tumor and the inked
circumferential margin were specifically taken if dis-
tances below 0.5 cm were observed on dissection. Com-
pleteness of the mesorectum was assessed (starting in
2002) and was scored as good or moderate (grading as
in reference [7]; analogous to Mercury 1 or 2) in 90.4%
of the cases evaluated for this feature and poor (Mercury
3) for the remaining 9.6%. Mesorectal fat was cleared in
acetone overnight to allow maximum harvest of lymph
nodes (mean 15.17, median 15, range 4 to 43). Surgical
pathology reports typed and staged the tumors according
to the TNM system. The first author made 65.4% of the
dissections and initial pathology reports; the remaining re-
ports were in equal proportions by three other consultant
pathologists.
At the beginning of the study, the archived slides were
retrieved and a study review was made, with request for
additional sections from the archived paraffin-blocks if
considered appropriate. This study review had three ob-
jectives: First, to confirm (or modify) the initial path-
ology reports and to add information on angioinvasion
(L- and V-status) and perineural invasion (Pn-status) if
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tomorphological features:
1. Regression grading as published by Dworak. [1]
2. Maximum extramural extension of vital/non-regressed
tumor, measured in millimeters and classified as
absent, early (<3 mm), progressed (3 to 10 mm), or
deep (>10 mm).
3. Minimum distance to the circumferential resection
margin (measured in millimeters) and classified
as >3 mm, 1 to 3 mm, or <1 mm.
4. Transgression of the lymph node capsule by metastatic
tumor.
Third, in the course of the study review for each case,
the H&E stained section that contained a full transection
of the lesion and the maximum of vital tumor was se-
lected for morphometric study.
Morphometric studies
The slides selected during the study review were scanned
with a Mirax slide scanner (Zeiss, Jena, Germany) and
converted to digital images in JPEG format that allowed
further processing with ImageJ (public domain software at
http://rsb.info.nih.gov/nih-image) for morphometry. In
these digital images, a ‘tumor bed’ was delineated as
the area of interest (AOI). These AOIs contained the
complete area of vital and/or regressed tumor from
immediately below the superficial ulceration or re-
epithelialized surface to the deepest border that in a
given section could be traced by a continuous line.
Avital/regressing tumor was defined by fibrotic tissue
with histiocytic inflammatory infiltration that replaced
the preexisting muscularis propria or extramural fat,
often interspersed with areas of necrosis or dystrophic
calcifications or mucin ‘lakes’; pure fibrosis which may
well be radiation fibrosis only was not taken as regres-
sing tumor.
For this ‘tumor bed’, a numeric index (tumor area frac-
tion (TAF)) was calculated based on a point counting
method as follows (see Figure 1 for some exemplary
screenshot images taken during the procedure):
1. Delineate an area of interest (AOI) representing vital
and/or regressed tumor (the ‘tumor bed’) with the
free-hand tool; clear the outside (ImageJ pull-down:
edit ➔ clear outside).
2. Measure the number of pixels contained in this AOI
(ImageJ pull-down: measure).
3. Place a ‘grid’ made up of points over the AOI
(ImageJ pull-down: plugins ➔ particle analysis ➔ grid;
specify grid characteristics as implemented with the
selection menu); space points at 10.000 to 2,500 per
pixel2, depending on the amount of vital tumor.4. Calculate the total number of grid points contained
in the AOI with the information from numbers 2
and 3.
5. Count the number of grid points co-localizing with
vital tumor cells (‘hits’) by systematically moving
through the image; magnify as appropriate with the
ImageJ magnifying tool to allow discrimination of
tumor from the stroma.
6. Divide the number of ‘hits’ by the total number of
points contained in the AOI to obtain the TAF.
Resolution of histological detail afforded by this
method is good, and the evaluations could be made with
confidence. The evaluations were made by the patholo-
gist among the authors (FP); except for a selected set of
training cases (N = 10) to test precision/reproducibility
of the method, for each case, the evaluation was per-
formed once. To test precision/reproducibility of the
method, a re-evaluation was done with ten of the cases.
The re-evaluations included delineation of the ‘tumor
bed’. A scatter graph plotting first vs. second evaluation
and a Bland-Altman plot are provided as Additional file
1: Figure S1 and Additional file 2: Figure S2.
TAFs obtained for tumors of the study series were
compared to cases from a control series of colorectal
carcinomas that had not undergone preoperative treat-
ment. This control series consisted of a total of 45 cases
taken from the archives: 15 colorectal non-mucinous
adenocarcinomas with an invasive border of the expan-
sive type, 15 non-mucinous adenocarcinomas with an
invasive border of the infiltrative type (see reference [8]
for details on invasive margin typing), and 15 mucinous
carcinomas.
Statistical evaluations
All data were entered into a SPSS data bank (IBM SPSS
Statistics 22). Relative risks for histopathological features
for local recurrence were calculated from cross tabula-
tions of classified data. Survival analyses were carried
out according to the Kaplan-Meier method and signifi-
cance testing was done by the log rank test.
Results
Clinicopathological features
This study includes 104 patients fulfilling the inclusion
criteria specified above. Clinical data and the patho-
logical data collected during the study review are sum-
marized in Table 1. Complete regression of the primary
tumor (ypT0) was seen in nine of the cases (Dworak
regression grade (DRG) 4, 8.7%), although there remained
vital nodal metastases in one case (that is, stage III disease)
and distant metastases in two cases (stage IV disease).
Regression of most of the primary tumor (DRG 3) was ob-
served in another 17 cases (16.3%). According to a widely
Figure 1 Screenshots illustrating the morphometric evaluation of scanned slides using ImageJ (see toolbars). (A) Panoramic view of the scanned
slide. Note the area of interest delineated with a yellow line using the free-hand tool. Grid overlay for point counting has already been done. The
asterisk indicates the area enlarged in (B) where grid points co-localizing with tumor cells (‘hits’) can be counted.
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Table 1 Clinical and pathological data
DRG0 DRG1 DRG2 DRG3 DRG4
Tumor location
Upper rectum 0 2 3 0 0
Middle rectum 1 15 20 6 2
Lower rectum 0 13 24 11 7
Type of surgery
Anterior resection 1 24 32 8 7
Amputation 0 6 15 9 2
UICC TNM stage
Stage 0 0 0 0 0 6
Stage I 0 6 9 6 0
Stage II 0 8 8 5 0
Stage III 1 13 17 3 1
Stage IV 0 3 13 3 2
Depth of infiltration by ypT
ypT0 0 0 0 0 9
ypT1 0 1 1 4 0
ypT2 0 6 12 6 0
ypT3 1 21 34 7 0
ypT4 0 2 0 0 0
Depth of extramural extension,
vital tumor
None 0 7 13 10 9
Early (<3 mm) 0 2 10 5 0
Progressed (3 to 10 mm) 1 16 19 2 0
Deep (>10 mm) 0 5 5 0 0
Nodal status (ypN)
ypN0 0 15 20 13 7
ypN1 1 7 17 3 1
ypN2 0 8 10 1 1
Lymphatic spread (L)
Absent 0 25 43 17 9
Present 1 5 4 0 0
Venous angioinvasion (V)
Absent 0 21 37 15 8
Present 1 9 10 2 1
Perineural spread (Pn)
Absent 0 24 41 17 8
Present 1 6 6 0 1
Distance towards CRMa,b
>3 mm 1 22 35 17 8
1 to 3 mm 0 4 5 0 0
<1 mm 0 4 6 0 1
Local recurrence
Negative 1 28 40 14 9
Table 1 Clinical and pathological data (Continued)
Positive 0 2 6 2 0
Death of disease
Negative 0 23 22 12 8
Positive 1 7 24 4 1
aCRM, circumferential resection margin; bMeasurement not possible for technical
reasons in one case. DRG, Dworak regression grade.
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total regression can be combined in the category of ‘major
regression’. This totalled at 24.9% in this series.
Morphometric studies
TAFs were determined for the rectal cancers and the
control cases, they are plotted in Figure 2. In this figure,
cases are grouped by DRG and the control cases as non-
mucinous adenocarcinomas (with invasive margins of
the expansive or infiltrative type) or mucinous adenocar-
cinomas. As can be gleaned from this figure, a clear-cut
effect of neoadjuvant treatment in terms of reduced
TAFs as compared to the control cases was observed for
all rectal cancers classified as DRG1 to 4; although, not-
ably, the TAFs determined for about half of the mucin-
ous adenocarcinomas were in the range of values
observed for rectal cancers classified as DRG1 or DRG2.
Furthermore, it should also be noted that TAFs of non-
mucinous adenocarcinomas with an invasive border of
the infiltrative type were well below the TAFs of expan-
sive type carcinomas.
TAFs were distributed continuously towards TAF = 0
(that is, complete regression) as is well appreciated in
the plot in Figure 2a and by plotting the data on a log
scale for the more regressed cases (DRG2 and DRG3,
Figure 2b). Notably, TAFs overlapped considerably be-
tween DRG groups. Thus, regression grading in surgical
pathology essentially amounts to an arbitrary division of
a ‘morphological continuum’.
Prognostic role of tumor regression and other
histopathological features
Two of the 104 patients included in the histopatho-
logical and morphometric studies died of perioperative
complications and were excluded from the survival ana-
lyses. Local recurrence was observed in 10 of the
remaining 102 patients, two and four with additional
distant metastases at first presentation or during follow-
up, respectively. In two cases, local recurrence was
proven by biopsy; in eight cases the diagnoses were
made on imaging studies. As can be seen in Table 2,
where details for these patients’ tumors are listed, all pa-
tients with local recurrence during follow-up had rectal
cancer at a well advanced stage, frequently with a com-
bination of several risk factors. Relative risks for local
Figure 2 Scatter plot of TAFs. In (A) all TAFs obtained in this study
are grouped by Dworak regression grades (study cases) or histotypes/
type of invasive margin (control cases). Gray bars represent the
medians within the groups. In (B) TAFs for cases DRG2 and DRG3
are plotted on a logarithmic scale. This expansion of the data
overlay between groups is further appreciated. Note that assigning
regression grade DRG2 to one tumor with a TAF well below the
rest was due to a fairly large albeit single remaining vital tumor
complex. Exp, expansive; inf, infiltrative; muc, mucinous; TAF, tumor
area fractions; DRG, Dworak regression grade.
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were found to be significant for the following risk factors:
perineural infiltration (Pn1) and capsule transgressing
mesorectal lymph node metastases and/or mesorectal
tumor deposits. By contrast, tumor regression, extensionof the tumor towards the circumferential resection margin
(R1), lymphatic spread (L1), or venous angioinvasion (V1)
as well as location of the tumor in the lower rectum or
amputation as operative procedure were not found to be
significant risk factors for local recurrence in this series.
Furthermore, depth of extramural extension and TAF did
not differ significantly between cases with and without
local recurrence (T-test).
During follow-up, death of disease was observed for
37 of the 102 patients. Kaplan-Meier survival curves
with extent of regression as prognostic factor are plotted
in Figure 3. In this analysis, the 20% of the cases with
lowest TAFs (≤20th percentile) were defined as having a
major regression, the remainder as minor responders. As
can be seen in Figure 3, survival for patients with major
regressions were better, although significance by log rank
test was not reached (P = 0,056). Defining DRGs 4 and 5
as major responders a similar result was observed, again
not significant by log rank test. TNM stage was a strong
and statistically significant prognosticator.
Discussion
High interobserver variability is a drawback of current
systems for grading tumor regression of neoadjuvantly
treated rectal cancer [3], prompting this study to try for
a more objective approach. We employed a traditional
point counting method coupled with modern electronic
image processing. Scanned sections were made available
for virtual microscopy, an area corresponding to the
‘tumor bed’ was selected, measured, and covered with a
grid for counting ‘hits’ on vital tumor that allowed calcu-
lating a TAF. Essentially, the procedure starts from the
idea that also underlies regression grading approaches
that make estimates of vital remaining tumor [2], yet by
making measurements instead of subjective assessment
of residual viable tumor, it goes beyond in two important
aspects. First, precision and reduced subjectivity in these
evaluations are an advantage. The second advantage of
this morphometric approach is that it supplies numeric
data which are suitable for additional exploratory ana-
lyses. However, doubtless this method is not completely
without an arbitrary/subjective element. Namely, there
remains the selection of the slide to study by morphom-
etry, a well known confounder in regression grading [4].
The guideline applied here was to select the slide with
the maximum burden of vital tumor. Furthermore, delin-
eation of the ‘tumor bed’ remains a subjective procedure
although reproducibility appeared not to be compromised
much when repeat evaluations were made (see Additional
file 1: Figure S1 and Additional file 2: Figure S2).
Plotting the numeric tumor regression data of the
cases included in this study gives an easy answer to why
pathologists have failed to conceive a regression grading
system endowed with high interobserver reproducibility;
Table 2 Clinicopathological features of cases with local recurrence
OP Mesorectuma UICC stage METb TAF (DRG) ypT Extramural spread (mm) ypN Satc L V Pn R
AR ND 3 0 .0001 (3) 2 0 1 None 0 0 0 >3 mm
AR Good 3 1 .0703 (1) 3 6 2 Positive 0 1 1 >3 mm
AR ND 3 0 .0185 (1) 3 10 2 Positive 0 1 1 0 mm
Amp Good 3 0 .0095 (2) 2 2 1 Positive 0 1 1 >3 mm
AR Good 3 1 .0092 (2) 3 5 1 Positive 0 0 0 >3 mm
AR Good 3 1 .0328 (2) 3 7 2d Positive 1 0 1 <1 mm
AR Good 3 1 .0040 (2) 3 5 2 Positive 0 0 0 >3 mm
Amp Moderate 3 0 .0514 (2) 3 15 1 None 0 1 1 >3 mm
Amp Good 4 NA .0003 (3) 1 0 1 None 0 0 0 >3 mm
AR Good 4 NA .0140 (2) 3 10 1 None 0 0 0 >3 mm
aState of the mesorectum, analogous to the Mercury classification; bDistant metastases during follow-up; cSat, vital satellite nodules; dwith extranodal spread of vital
tumor. NA, not applicable; ND, no data.
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Figure 2: the amount of residual tumor after neoadjuvant
chemoradiation determined for a given case can fall any-
where within a broad continuous range. With the excep-
tion of cases with complete regression (8.7% in this
series), indeed, there are not any natural cut points that
allow meaningful distinctions between ‘grades’. Accord-
ingly, overlap of TAFs between DRGs is considerable.
From a tumor biological point of view this is not sur-
prising, but as far as we are aware, this because of the
lack of morphometric data has not been and could not
be spelt out clearly. Another interesting aspect derives
from these quantitative data when comparing them with
the TAFs obtained for the control cases, particularly so if
histotypes (adenocarcinoma vs. mucinous carcinoma)
and phenotypes of invasion (expansive vs. infiltrative) are
also taken into account. Only TAFs obtained for adenocar-
cinomas with an invasive border of the expansive typeFigure 3 Kaplan-Meier survival curves with death of disease as clinical
end-point and stratification according to TAFs. Tumors with TAFs
below the 20th percentile were classified as major responders; the
remainder as minor responders.were well above the range of neoadjuvantly treated rectal
cancers, but carcinomas with an invasive borders of the
infiltrative type overlapped into the DRG1 group and mu-
cinous carcinomas even into DRG2. Obviously, when
examining the resection specimens, pathologists cannot
know what type of cancer there was at the beginning of
neoadjuvant chemoradiation. Thus, when trying to grade
regression, apparently we are dealing with a situation
where end-points differ considerably between cases, but
the starting-points, unknown for each case, also are very
different! By adding this underrecognized aspect into the
account, regression grading is coming to light as really
quite a conundrum.
What then could be a ‘major regression’? In a meaning-
ful definition, assessment would have to rely on an object-
ive and reproducible method, and a major regression thus
determined would have to imply a favorable prognosis
with significance. Two approaches to this issue can be
found in published clinicopathological studies. By one ap-
proach, cases with complete regression are combined with
those with minimal residual vital tumor (TRGs 1 and 2 in
the Mandard system; DRGs 4 and 5 in the Dworak sys-
tem). Clearly, this approach is compromised by problems
with reproducibility/objectivity, as demonstrated by the in-
terobserver studies [3] and explained by the morphomet-
ric data presented here. Nevertheless, in most [9-13] but
not all [14,15] studies, a major regression thus defined was
found to predict a favorable clinical course with statis-
tical significance. Defining cases with TAFs ≤20th per-
centile as major responders or combining DRGs 4 and
5, we observed the same result, although statistical sig-
nificance was not quite reached (as in references
[14,15]). Notably, our attempt to use the numeric re-
gression data for prognostication with a cutoff did not
perform better than traditional regression grading. Lack
of statistical significance in the present series may well
have been due to the relatively low number of cases,
Prall et al. World Journal of Surgical Oncology  (2015) 13:155 Page 8 of 9similar to the studies by Pucciarelli et al. and Hav et al.
[14,15]. Furthermore, our series included a fairly large
proportion of patients with synchronous distant metas-
tases that may be limiting in the clinical course and
would not be targeted by the neoadjuvant therapy as ef-
ficiently as the primary tumor and its deposits in the
pelvic region. By the other approach, major regressions
are restricted to cases with complete sterilization of the
tumor (see reference [16] for meta-analyses) At first
sight, this may seem a very robust definition and a nat-
ural cutoff, vindicated further by the prognostic signifi-
cance demonstrated by the meta-analyses. However, as
pointed out by Bateman et al. [17], a very thorough and
dedicated histopathological workup of the specimens is
mandatory for this, giving rise to the mischievous
thought that, in view of very high rates of complete
responses in some of the series basing these meta-
analyses, perhaps sufficient diagnostic rigor in the de-
terminations of complete pathological responses had not
been executed in all the studies. Taken together, Patho-
logical complete response: still a relevant end-point in rec-
tal cancer? is a legitimate question to ask [18].
It must be realized that in all the clinicopathological
studies on tumor regression, TNM stage was found to
be more important as a prognostic factor than tumor re-
gression, and this was our observation, too. Thus, careful
histopathologic workup of the specimens appears to be
the most important issue. It may indeed even be worth-
while to invest more effort into this: in this series, for
example, perineural invasion and capsule transgression
of lymph node metastases/perirectal tumor deposits
were found to be a strong adverse prognosticator for
local recurrence. Similarly, tumor deposits (interpreted
as tumor fragmentation as opposed to tumor shrinkage)
were a significant negative histopathological factor in a
recent study [15].Conclusions
In conclusion, we showed in this study that morphomet-
ric assessment of tumor regression is feasible, explaining
why conventional regression grading is so difficult to
perform. Furthermore, assessment of tumor regression,
by subjective grading or morphometry, apparently does
not convey major prognostic information, at least not
convincingly beyond careful histopathological tumor sta-
ging. This observation casts doubt on expending too
much effort on developing this aspect of the pathomor-
phological workup of the resection specimens.Additional files
Additional file 1: Figure S1. Scatter plot of TAFs obtained by re-evaluation
of a selected set of cases.Additional file 2: Figure S2. Bland-Altman plot of re-evaluations. The
dashed horizontal line in the middle signifies the mean of the differences;
the dashed horizontal lines above and below signify +/− 2 s, respectively.
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